AVEO Pharmaceuticals Inc. pulled in a whopping $125 million up front in a deal with Astellas Pharma Inc. for Phase III-stage tyrosine kinase inhibitor tivozanib, proving that strong data and promising market potential can prevail even in a buyer's market.